[EN] SALICYLATE CONJUGATES USEFUL FOR TREATING METABOLIC DISORDERS<br/>[FR] CONJUGUÉS DE SALICYLÉS UTILES POUR LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
申请人:GENMEDICA THERAPEUTICS SL
公开号:WO2009138437A1
公开(公告)日:2009-11-19
The present invention is directed to methods for treating metabolic disorders with compounds that are salicylate conjugates.
[EN] PHARMACEUTICAL COMBINATIONS INCLUDING ANTI-INFLAMMATORY AND ANTIOXIDANT CONJUGATES USEFUL FOR TREATING METABOLIC DISORDERS<br/>[FR] COMBINAISONS PHARMACEUTIQUES CONTENANT DES CONJUGUÉS ANTI-INFLAMMATOIRE- ANTIOXYDANT ET DESTINÉES À ÊTRE UTILISÉES EN VUE DU TRAITEMENT D'AFFECTIONS MÉTABOLIQUES
申请人:GENMEDICA THERAPUTICS SL
公开号:WO2013037985A1
公开(公告)日:2013-03-21
One aspect of the present invention is a pharmaceutical combination comprising (a) an anti-inflammatory agent/anti-oxidant agent conjugate; and (b) an insulin secretogogue, an insulin sensitizer, an alpha-glucosidase inhibitor, a peptide analog, or a combination thereof. Another aspect of the invention relates to methods of treating metabolic disorders with such conjugates.
Alkylated resveratrol prodrugs and metabolites as potential therapeutics for neurodegenerative diseases
its low efficacy and bioavailability. Here, we have designed and synthesized alkylated resveratrol prodrugs combining structural modification to improve antioxidant and anti-inflammatory properties and the preparation of prodrugs to extend drug bioavailability. For comparison we also studied resveratrol prodrugs and alkylated resveratrol derivatives. Methylated and butylated resveratrol derivatives showed